Dr. Reddy's Laboratories Limited (RDY) Cash Flow Statement

The OCF/NI ratio of -0.21 in 2027Q1 marks a stark reversal from the 1.38 ratio in 2025Q4, indicating that reported profits are not being converted into cash. The $12.0B negative working capital change dwarfs the net income, suggesting aggressive inventory build-up or delayed collections that may not be sustainable. This divergence warrants close monitoring as it could signal either a one-time seasonal effect or a structural deterioration in cash generation.

The FCF trajectory shows a clear deterioration, with the 2027Q1 FCF of -$4.6B contrasting sharply with the positive $10.7B in 2026Q4. This decline is driven by both negative operating cash flow and elevated capex of $3.4B, which at 4.2% of revenue remains elevated relative to the 0.1% in 2024Q4. The negative FCF margin suggests the company is consuming cash to fund operations and investments, which may pressure future dividend capacity or require external financing.

The elevated capex-to-revenue ratio, though lower than the 14.8% peak in 2026Q4, indicates continued investment in manufacturing capacity and regulatory compliance. This spending appears growth-oriented, targeting biosimilars and GLP-1 drugs, but it coincides with negative operating cash flow, creating a funding gap. Investors should assess whether this capex will generate sufficient returns to offset the current cash burn, especially given the strained profitability.

The negative working capital swing of $12.0B in 2027Q1 is unprecedented compared to the $584M positive contribution in 2025Q4, indicating a massive cash absorption. This could reflect inventory stocking ahead of anticipated launches or slower collections from US wholesalers amid pricing pressures. The pattern suggests that the company's cash conversion cycle is lengthening, which may indicate weakening demand or channel destocking, and warrants close monitoring for reversal.

The acquisition activity, particularly the massive $51.8B outflow in 2025Q2, suggests management is deploying capital into bolt-on deals to bolster the pipeline, but this comes at a time when operating cash flow is negative. Dividends and buybacks have been minimal or absent in recent quarters, with only $41.1M in dividends in 2026Q4, indicating a prioritization of growth investments over shareholder returns. This aggressive deployment may strain liquidity if cash generation does not recover.

The cumulative gap of $14.4B between net income and operating cash flow suggests that earnings quality is weaker than headline profits imply, with significant non-cash items or working capital drags. This divergence is most pronounced in 2027Q1, where net income of $4.5B contrasts with -$927M operating cash flow, highlighting a potential overstatement of profitability. Investors should monitor whether this gap narrows as working capital normalizes, or if it signals deeper issues with revenue recognition or collectability.